Revolution Medicines' Daraxonrasib Doubles Pancreatic Cancer Survival in Pivotal Phase 3 Trial
Summary
Revolution Medicines announced highly positive results from a late-stage clinical trial for its experimental oral drug, daraxonrasib, in patients with pancreatic cancer. The trial demonstrated a median overall survival of 13.2 months for patients receiving daraxonrasib, significantly outperforming the 6.7 months achieved by standard intravenous chemotherapy. These results not only show a substantial survival benefit but also exceeded analyst expectations of 11-12 months, validating the drug's potential. This pivotal data significantly de-risks daraxonrasib, which targets RAS mutations prevalent in pancreatic cancer, and positions it for a potential market opportunity estimated at over $10 billion. The company plans to submit these data to global regulatory authorities, including the FDA, under a priority voucher. Investors will now closely monitor the regulatory submission process and potential approval timelines, as well as any renewed M&A speculation given the drug's strong performance.
At the time of this announcement, RVMD was trading at $97.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.1B. The 52-week trading range was $29.98 to $124.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.